P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO Volume : 5 Issue : 1 Year : 2021
EJMO. 2021; 5(1): 59-62 | DOI: 10.14744/ejmo.2021.96518

Cost-Effectiveness of Pembrolizumab in Combination with Platinum-Based Chemotherapy in First-Line for Squamous and Nonsquamous Non Small-Cell Lung Cancer. Far from Economic Sustainability

Jacopo Giuliani1, Andrea Bonetti1
1Department of Oncology, Mater Salutis Hospital – Az. ULSS 9 Scaligera, Legnago (VR), Italy

Objectives: To assess the pharmacological costs of pembrolizumab in association with chemotherapy as first-line treatment in non small-cell lung cancer (NSCLC). Methods: Pivotal phase III randomized controlled trials (RCTs) were considered. Differences in progression free survival (PFS) between the different arms were calculated and compared with the pharmacological costs needed to get one month of PFS (incremental cost-effectiveness ratio, ICER). Results: One thousand one hundred and seventy five patients were included.Differences in costs between the 2 arms with the use of pembrolizumab were 37 009 € for squamous NSCLC and 45 234 € for nonsquamous NSCLC, with a cost of 23 131 € and 11 598 € per month of PFS-gain in the overall population for squamous and nonsquamous NSCLC, respectively and with a progressively lower cost per month of PFS-gain in the transition from PD-L1< 1% (37 009 €) to PD-L1 of 1 to 49% (18 505 €) to PD-L1? 50% (9739 €) in squamous and NSCLC. Conclusion: At the actual prize, pembrolizumab in combination with chemotherapy is not cost-effective in first-line for both squamous and nonsquamous NSCLC. A reduction in pharmacy cost is mandatory. Keywords: Cost of drugs, NSCLC, pembrolizumab


Cite This Article

Giuliani J, Bonetti A. Cost-Effectiveness of Pembrolizumab in Combination with Platinum-Based Chemotherapy in First-Line for Squamous and Nonsquamous Non Small-Cell Lung Cancer. Far from Economic Sustainability. EJMO. 2021; 5(1): 59-62

Corresponding Author: Jacopo Giuliani

Full Text PDF PDF Download
EJMO & EJMO